Why the study?
Does low-dose cabergoline cause significant valvular thickening or regurgitation in patients with prolactinoma?
Population
50 prolactinoma patients, 30 male, 20 female, mean age 51.2 +/- 2.2 years
Comparison
Cabergoline at doses commonly used for… vs Age- and sex-matched controls with normal left…
Design
Case-control
Follow-up
6.6 +/- 0.5 years (treatment duration)
Key result
Long-term administration of cabergoline for prolactinoma was not associated with increased mitral valve tenting area, valvular thickening, or significant regurgitation compared to matched controls.
Authors
Loading...
Supports valvular safety of long-term low-dose cabergoline in prolactinoma; leaves open confirmation in prospective cohorts.
Case-Control (n=50)
Does low-dose cabergoline cause significant valvular thickening or regurgitation in patients with prolactinoma?
Long-term use of low-dose cabergoline for prolactinoma treatment does not appear to increase the risk of significant cardiac valvulopathy.
Herring et al. (2008) conducted a case-control in prolactinoma (n=50). Cabergoline vs. age- and sex-matched controls with normal left ventricular function was evaluated on prevalence of significant valvular thickening (> 0.5 cm) and regurgitation, and mitral valve tenting area and height. Long-term administration of cabergoline for prolactinoma was not associated with increased mitral valve tenting area, valvular thickening, or significant regurgitation compared to matched controls.